Patents Examined by Paul V. Ward
  • Patent number: 11072600
    Abstract: The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: July 27, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ATLASMEDX, INC.
    Inventors: Csaba J. Peto, David M. Jablons, Tsze Tsang, Hassan Lemjabbar-Alaoui
  • Patent number: 11071735
    Abstract: This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug thereof, or pharmaceutically acceptable salt or ester of said compound or pro-drug, wherein the compound is an inhibitor of glucose uptake. In particular aspects, the present invention provides a method of treating inflammatory conditions and autoimmune diseases in a mammal, and preferably a human, in which the glucose uptake inhibitor modulates the glucose transport of GLUT1 and GLUT3.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 27, 2021
    Assignee: KADMON CORPORATION, LLC
    Inventors: Ji-In Kim, Kellen L. Olszewski, Anthony M. Barsotti, Masha V. Poyurovsky, Kevin G. Liu, Koi Morris, Xuemei Yu
  • Patent number: 11059785
    Abstract: Disclosed are chelating co-polymer compositions that are soluble in aqueous media and chelate essential metals, methods of preparation and uses thereof. The chelating compositions are comprised of two or more different monomers, at least one of which possesses metal binding or metal chelating activity. The chelating compositions are synthesized by reversible addition-fragmentation transfer (RAFT) polymerization with the aid of a suitable RAFT-mediating agent. Also described are chelating compositions that comprise hydroxypyridinone chelating groups. The ability of the chelating compositions to bind metals affects the activity of a living cells and organisms, which require the metals for cellular functions.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: July 13, 2021
    Assignee: CHELATION PARTNERS INCORPORATED
    Inventors: Bruce E. Holbein, M. Trisha C. Ang, Dnyaneshwar Vithoba Palaskar, Ganugapati Satyanarayana, Gireesh Mahandru, S. Vijaya Bhaskara Reddy, Sazid Ali
  • Patent number: 11059795
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: July 13, 2021
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
  • Patent number: 11053240
    Abstract: Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 6, 2021
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventors: Lixin Li, Huiping Guan
  • Patent number: 11053202
    Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 6, 2021
    Assignee: Vectus Biosystems Limited
    Inventor: Karen Annette Duggan
  • Patent number: 11053234
    Abstract: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: July 6, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David Norman Deaton, Yu Guo, Ashley Paul Hancock, Christie Schulte, Barry George Shearer, Emilie Despagnet Smith, Eugene L. Stewart, Stephen Andrew Thomson
  • Patent number: 11052092
    Abstract: The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases or cholestatic diseases, such as e.g. arthitis and asthma.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: July 6, 2021
    Assignee: Genfit
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
  • Patent number: 11052377
    Abstract: A long-life catalyst which can be easily and inexpensively manufactured and has high activity and suppressed leakage of metal. A catalyst according to some embodiments includes: a substrate; and a first metal atom as a catalytic center. The substrate contains a non-metallic atom and a second metal atom, and the non-metallic atom is any one selected from the group consisting of a group 15 element, a group 16 element and a group 17 element.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: July 6, 2021
    Assignee: TOYO GOSEI CO., LTD.
    Inventors: Shin-ya Tashita, Takashi Miyazawa
  • Patent number: 11053257
    Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1?-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: July 6, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Kazuhiro Miwa
  • Patent number: 11046649
    Abstract: The present invention relates to bicyclic compounds and compositions and methods which may be useful as inhibitors of IDO1, IDO2, and TDO for the treatment or prevention of diseases such as cancer.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 29, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Timothy McAfoos, Jason Bryant Cross, Michael J. Soth
  • Patent number: 11046661
    Abstract: The present invention relates to a method for producing a lactam compound from dioxazolone in the presence of a catalyst having a particular ligand, and to a lactam compound produced thereby, and can produce a lactam compound with excellent selectivity and an excellent yield by using the combination of a starting material having a particular functional group and a particular catalyst having a particular ligand.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: June 29, 2021
    Assignees: INSTITUTE FOR BASIC SCIENCE, KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sukbok Chang, Seung Youn Hong, Yoon Su Park, Yeongyu Hwang, Yeong Bum Kim
  • Patent number: 11046658
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 29, 2021
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • Patent number: 11046701
    Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: June 29, 2021
    Assignee: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Yan Hao, Renyan Zhang, Huiping Pan, Fuzhi Zhang, Shijie Yin, Juping Ding, Qiang Yu
  • Patent number: 11040925
    Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: June 22, 2021
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • Patent number: 11034692
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • Patent number: 11034670
    Abstract: The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 15, 2021
    Assignee: Mitobridge, Inc.
    Inventors: Taisuke Takahashi, Arthur Kluge, Bharat Lagu, Nan Ji
  • Patent number: 11028084
    Abstract: A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-?B kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-?B) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-?B activation.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: June 8, 2021
    Assignees: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Forschungsverbund Berlin e.V
    Inventors: Claus Scheidereit, Michael Willenbrock, Peter Lindemann, Silke Radetzki, Jens-Peter Von Kries, Marc Nazare
  • Patent number: 11026929
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 8, 2021
    Assignee: Keto Patent Group, Inc.
    Inventors: Ryan Lowery, Jacob Wilson, Terry LaCore
  • Patent number: 11021482
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: June 1, 2021
    Assignee: Adaris Therapeutics, Inc.
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee